Mazdutide 10 mg

Mazdutide 10mg peptide is a synthetic dual receptor agonist designed as an oxyntomodulin-analog research compound that engages both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. Through balanced activity at these two receptor systems, mazdutide is investigated as an experimental research compound for studying incretin-pathway research, glucagon receptor signaling research, and energy-metabolism research in controlled laboratory settings.

Research interest in Mazdutide 10mg peptide has focused on how dual GLP-1 and glucagon receptor engagement may modulate downstream metabolic-pathway research models in ways distinct from selective GLP-1 receptor agonism. Mechanistic data indicate that mazdutide interacts with both receptors through structural features inherited from oxyntomodulin pharmacology, supporting laboratory research studies of receptor-balance signaling, glucose-signaling research, and energy-expenditure research models (Ji et al., 2022, eClinicalMedicine; Zhang et al., 2025, structural pharmacology research).

Beyond incretin-pathway research, Mazdutide 10mg peptide has also been investigated in research models examining hepatic lipid-metabolism research, glucose-signaling markers, and combined receptor-pathway adaptation. These investigations have positioned mazdutide as an experimental research compound of interest in studies of dual agonist receptor pharmacology and oxyntomodulin-pathway signaling research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Mazdutide (also referenced in research literature as IBI362 and LY3305677) is a synthetic dual receptor agonist research peptide engineered as an analog of oxyntomodulin, a proglucagon-derived endogenous hormone that engages both the GLP-1 receptor and the glucagon receptor. The mazdutide scaffold incorporates a fatty-acid side chain that extends the molecule's pharmacokinetic profile, enabling its use in once-weekly research dosing schedules.

The rationale behind oxyntomodulin-analog research is that combined GLP-1 and glucagon receptor signaling may modulate energy-metabolism research models through complementary pathways. GLP-1 receptor activity is investigated for its association with glucose-signaling research and central neuroendocrine pathways relevant to energy-balance research. Glucagon receptor activity is investigated for its association with hepatic lipid-metabolism research and energy-expenditure research models.

This positioning at the intersection of two established proglucagon-derived receptor systems has made mazdutide an experimental research compound of considerable interest in laboratory research studies of dual agonist receptor pharmacology, receptor-balance signaling, and integrated metabolic-pathway research.

1. GLP-1 Receptor Engagement

Mazdutide engages the GLP-1 receptor, a class B G-protein-coupled receptor expressed across pancreatic, central, and peripheral tissues in research models. GLP-1 receptor signaling research is associated with glucose-dependent insulin-signaling pathways and central neuroendocrine modulation relevant to energy-balance research.

2. Glucagon Receptor Engagement

Mazdutide also engages the glucagon receptor, which is expressed across hepatic and adipose research tissues. Glucagon receptor signaling is investigated in laboratory research studies for its association with hepatic glucose-output research, lipid-metabolism research, and energy-expenditure research models.

3. Oxyntomodulin-Pathway Mimicry

Because mazdutide is engineered as an oxyntomodulin analog, it mirrors the endogenous dual receptor engagement profile of proglucagon-derived hormones. Structural-pharmacology research has characterized how mazdutide interacts with GLP-1 and glucagon receptors through molecular docking and receptor-binding research models (Zhang et al., 2025).

4. Integrated Dual Agonist Signaling

By interacting with both receptor systems within a single molecule, mazdutide is investigated as a tool for studying receptor-balance pharmacology, downstream signaling crosstalk, and integrated metabolic-pathway adaptation in research models. The fatty-acid acylation extends the half-life of the molecule, supporting receptor-pharmacology research at extended timepoints.

Research Applications

Conclusion

Mazdutide represents an experimental research compound class of oxyntomodulin-analog dual receptor agonists that engage GLP-1 and glucagon receptors simultaneously. By integrating two proglucagon-derived receptor arms within a single peptide, mazdutide supports laboratory research studies of receptor-balance pharmacology and integrated metabolic-pathway signaling, making it a valuable research target for investigations of dual agonist receptor pharmacology and energy-metabolism research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.